NuSirt Biopharma
CompanyUnited States
NuSirt Biopharma develops 2 assets, the furthest in phase 2 (NS-0200 in hypertension). Mostly small molecule; based in the United States.
- 2
- Assets
- Furthest stage
- Phase 2
- 4
- Trials
- 4
- Signals
Pipeline
2Synergistic combination of leucine and metformin activating sirtuin and AMPK pathways to improve glycemic control.
Phase 2, no development reported, Small molecule, type 2 diabetes
Phase 2, hypertension, metabolic dysfunction-associated steatotic liver disease
Full company profiles: pipeline, trials, funding and people.
In the full profile
- Evidence behind the mechanisms2
- Trials4
- Signals7
- Similar companies6